65,437 trials
Acute Uncomplicated Plasmodium Falciparum Malaria
Primary: Part A and Part B: Number of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitological Response (ACPR) at Day 29 — 46; 45; 47; 47…
Diabetes Mellitus Type 2
Primary: Effect of Androgel Treatment on Relative Nuclear Factor kB Activity Compared to Placebo — 100; 100; 100; 236 Percent change from baseline
Advanced Solid Tumors
Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 1; 0; 2; 0 Participants
Breast Adenocarcinoma · Deleterious BRCA1 Gene Mutation · Deleterious BRCA2 Gene Mutation
Primary: Number of Participants With Overall Pathological Complete Response (pCR) — 7; 10; 3; 2 Participants
Schizophrenia
Primary: The Incidence of Overall Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation — 88; 15; 18; 18 Participants
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 26.1; 59.5; 57.3 Percentage of…
Physical Activity · Fundamental Motor Skills · Development, Child
Primary: App Adherence — 71; 87 percentage of activity breaks
Attention Deficit Hyperactivity Disorder
Primary: CASI-5 Parent-rated Composite Score — 1.49; 1.52; 1.18; 1.23 score on a scale
Cystic Fibrosis · Pancreatic Insufficiency
Primary: Change in Second-phase Insulin Response Derived From the Glucose-potentiated Arginine Test as a Measure of β-cell Sensitivity to Glucose at Baseline and at 6 Months…
Advanced Cancers
Primary: Progression-Free Rate at 4 Month — 25; 10; 44.4; 75 percentage of participants
Hormone Receptor Positive Breast Cancer
Primary: First-line Treatment: Progression-free Survival (PFS) — NA Months
Clostridium Difficile Infection
Primary: The Number of Cases of CDI — 103; 0 Participants
Infection, Hospital
Primary: Disinfecting Barrier Cap Compliance — 98.43 percentage of connector with compliance
Crohn Disease
Primary: Change in FCP in Group 2 Participants — 1501 mcg/g — p=1.0
ST Elevation Myocardial Infarction
Primary: Global Infarct Size — 5.453; 8.598; 9.004; 7.819 Percentage of global infarct size